Affiliation:
1. Department of Clinical Research Delhi Pharmaceutical Sciences and Research University (DPSRU) New Delhi India
2. Department of Pharmacology Delhi Pharmaceutical Sciences and Research University (DPSRU) New Delhi India
3. Centre for Precision Medicine and Pharmacy Delhi Pharmaceutical Sciences and Research University (DPSRU) New Delhi India
Abstract
AbstractAntiviral drugs are not known for drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome. The current study aims is to find out the association of antiviral drugs and their possible mechanism with DRESS. Data mining algorithms such as proportional reporting ratio that is, PRR (≥2) with associated χ2 value (>4), reporting odds ratio that is, ROR (≥2) with 95% confidence interval and case count (≥3) were calculated to identify a possible signal. Further, molecular docking studies were conducted to check the interaction of selected antiviral drugs with possible targets. The potential signal of DRESS was found to be associated with abacavir, acyclovir, ganciclovir, lamivudine, lopinavir, nevirapine, ribavirin, ritonavir, and zidovudine among all selected antiviral drugs. Further, subgroup analysis has also shown a potential signal in different age groups and gender. The sensitivity analysis results have shown a decrease in the strength of the signal, however, there was no significant impact on the outcome except for acyclovir. The docking results have indicated the possible involvement of human leukocyte antigen (HLA)*B1502 and HLA*B5801. The positive signal of DRESS was found with selected antiviral drugs except for acyclovir.
Subject
Infectious Diseases,Virology
Reference27 articles.
1. Practical aspects of signal detection in pharmacovigilance. Accessed July 2 2022.https://cioms.ch/wp-content/uploads/2018/03/WG8-Signal-Detection.pdf
2. Serious Adverse Drug Reactions and Safety Signals in Children: A Nationwide Database Study
3. Disproportionality Analysis for Pharmacovigilance Signal Detection in Small Databases or Subsets: Recommendations for Limiting False-Positive Associations
4. Pharmacovigilance Guidance Material. Accessed June 25 2022.https://allaboutpharmacovigilance.org/
5. Center for Drug Evaluation and Research. FDA adverse event reporting system (FAERS) public dashboard. US Food and Drug Administration. 2021. Accessed June 25 2022.https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-public-dashboard
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献